Conference Handbook Conference 2013 genesis 2013 WELCOME TO EDINBURGH BIOQUARTER

Designed to foster scientific creativity and encourage entrepreneurship among clinicians and researchers, BioQuarter combines world-class research from EDINBURGH LAUNCHES WORLD’S FIRST Edinburgh University’s College of Medicine and Veterinary Medicine with the long tradition of clinical VISUAL FIELD ANALYSER FOR CHILDREN excellence at NHS Lothian. Building one of Europe’s most In March 2012, Edinburgh significant concentrations of clinical and research assets, BioQuarter launched i2eye Diagnostics Limited, creators BioQuarter brings together a major teaching hospital, of the world’s first visual field medical school and three leading research institutes in analyser for children and hard- one location. Our seasoned business development team to-test patient groups. Based on research undertaken at the has spun out four new businesses and negotiated four University of Edinburgh and major industrial collaborations in less than two years, as NHS Lothian, this device enables well as generating 100 new product or business concepts young children’s field of vision to from its innovation competition. be tested accurately for the first the company has booked its first time, helping to pick up retinal orders and is set to take premises and optic nerve defects as well in our new incubator building, To find out more about how this commercialisation as certain forms of brain cancer. Nine the BioQuarter: partnership is building on Scotland’s successes Backed by private venture capital, www.i2eyediagnostics.com in life sciences, visit www.bioquarter.com Sponsors 3

Genesis 2013 Sponsors Contents Gold Sponsors Welcome 7

Keynote Speakers 8 - 9

Speaker Profiles 9 - 21

Programme 22-23

Floor Plan 24

Exhibitor List 25

Silver Sponsors The Genesis Talent Lounge 27

Exhibitor Profiles 31- 42

ON Hub 43

Corporate Patron Bronze Sponsors

Corporate Sponsors

Case Study Sponsors Partners

Supporters Wifi Sponsor

Media Partners Scotland. The home of Whisky and the Bionic Hand.

We’re the toast of the scientifi c community.

We’ve got quite a reputation for invention, innovation class academic institutions and purpose built science and improving people’s lives. Penicillin. Keyhole parks with some of the fi nest research facilities in surgery. The beta-blocker. The game of golf. It’s a the world. And passionate people with a hunger long list. And it’s still growing. In every sector from to win. We can develop your products and expand fi nance and electronics to our pioneering work in life your business. And that’s precisely why companies sciences, we strive to set standards. We have world- invest in Scotland. To hear what we can do for you, visit us at Genesis, Stand 6

SCOTLAND. SUCCESS LIKES IT HERE. Scotland. The home of Whisky and the BOSTON Johnson & Johnson Bionic Hand. Innovation Centers A new approach to advancing early-stage innovation We’re the toast of the scientifi c community.

CALIFORNIA

LONDON

Johnson & Johnson Innovation is positioned at the heart of the world’s most creative science hubs. We contribute to the life sciences ecosystem by being an integral member of regional scientifi c We’ve got quite a reputation for invention, innovation class academic institutions and purpose built science communities and taking a new approach to partnering to advance and improving people’s lives. Penicillin. Keyhole parks with some of the fi nest research facilities in early-stage innovation. Our goal: translate cutting edge ideas into surgery. The beta-blocker. The game of golf. It’s a the world. And passionate people with a hunger healthcare solutions for patients. long list. And it’s still growing. In every sector from to win. We can develop your products and expand SHANGHAI fi nance and electronics to our pioneering work in life your business. And that’s precisely why companies Together we can transform patient care. Find out more at sciences, we strive to set standards. We have world- invest in Scotland. www.jnjinnovation.com To hear what we can do for you, visit us at Genesis, Stand 6

SCOTLAND. SUCCESS LIKES IT HERE. © Johnson & Johnson Innovation, a division of Johnson & Johnson Finance Ltd. 2013 www.jnjinnovation.com

JJIC_1pageAd_WBT2013_A4_v3.indd 1 11/14/13 10:41 AM Go further, faster

Enterprise Europe Network London The route to new markets new funding new ideas www.een-london.co.uk || [email protected] || +44 (0) 20 7940 1512 Welcome 7

welcome

Dear Genesis 2013 Participant,

Welcome to our 13th Annual Genesis Conference: Harriet Fear CEO, One Nucleus Lucky for all of us I hope! The One Genesis 2013 continues to be a truly Nucleus team and I know you will make international networking exhibition. Go full use of the presentations, debate, We are delighted that UK Trade & networking and the exhibition hall to Investment has chosen to repeat the catch up with old friends and make success of their UKTI International Zone that we have brought in for some new ones, update yourselves the last two years and you will find it on trends in the sector and create and again this year in the Fleming Room. scope out new business opportunities. Commercial Officers (many of them further, I know times continue to be tough specialists in the sector) have joined us for many of you. As I always maintain, from around the world and are ready to however, there have always been a provide you with information, contacts myriad of challenges for companies and ideas in the partnering zone – all in this environment and you have free and impartial. always had to think creatively to forge ahead. The sector has many New for this year is our Talent Lounge - faster champions, exceptional entrepreneurs do check out Page 27 for more details. and individuals who are well placed to We are also continuing with the much meet the challenges and continue to appreciated (by us and delegates) strengthen the sector into the future. collaboration with the SCRIP team Many of them are here today. on Genesis, which saw its first ‘outing’ Here at One Nucleus we continue to at Genesis 2012. We have worked enhance our offer to our members and incredibly closely together on key the sector at large. At the heart of our elements of the event, evolving it strategy are two key threads: to enhance the knowledge sharing opportunities. The insights gained over Enterprise Europe Network • To work collaboratively with other the day will fuel the much anticipated organisations and cut down the Plenary Debate providing the panellists duplication of efforts to support our and delegates with the chance to share their suggestions to enhance success members and London at individual, company and sector wide • To create connections with level. international organisations who can help our members with their global I wish everyone an excellent event. The route growth and competitiveness The One Nucleus membership continues to grow and we remain the to new markets largest membership organisation in Europe (by some distance, with over 470 organisations as members). The new funding majority of our members are based in Cambridge and London. new ideas www.een-london.co.uk || [email protected] || +44 (0) 20 7940 1512 8 Keynote Speakers

Roel Bulthuis Senior Director, Head of Merck Serono Ventures at Merck Serono

Roel Bulthuis is Head of MS Ventures, the strategic venture capital fund of Merck Serono, which he established in 2009. MS Ventures also manages the Merck Serono Israel BioIncubator Fund and the Merck Serono Entrepreneur Partnership Program. Previously, Roel was a Director in the Biotech Investment Banking Team at Fortis Bank, based out of Amsterdam and New York. Before that, he worked at Devgen in Ghent, Belgium. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland.

Sir Salvador Moncada Professor of Experimental Biology and Therapeutics, Wolfson Institute for Biomedical Research, UCL

Salvador Moncada, MD, obtained his PhD in 1973 at the Royal College of Surgeons in London. He then moved to the Wellcome Research Laboratories where he initiated the Speaker Profiles work leading to the discovery of the enzyme thromboxane synthase and the vasodilator prostacyclin. He was also responsible for the identification of nitric oxide as a biological mediator and the elucidation of the metabolic pathway leading to its synthesis. Since 1996 Professor Moncada has directed the Wolfson Institute for Biomedical Research at University College London. He continued his research in the areas of mitochondrial biology and cell metabolism where he made significant contributions. His current research is concentrated in the area of cell proliferation. Professor Moncada is a Fellow of the Royal Society and a Foreign Associate of the National Academy of Science of the USA and in 2010 he received a Knighthood for his services to Science.

Mike Ward Global Director of Content, SCRIP Intelligence

Mike has been writing, analysing and commenting on the life sciences industry for the past 30 years. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry’s key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year.

Dr Louise Wood Deputy Director/Head of NHS Research Infrastructure and Industry R&D Relations, R&D Directorate , Department of Health

Louise is Deputy Director/Head of NHS Research Infrastructure and Growth in the Research and Development Directorate of the Department of Health and a member of the Directorate’s Senior Management Team. She has oversight responsibility for the NIHR- funded clinical research infrastructure in the NHS and partner universities and for the NIHR Office for Clinical Research Infrastructure (NOCRI). She co-chairs the Ministerial Industry Strategy Group (MISG) Clinical Research Working Group and is involved in all the major Government/industry/NHS initiatives established to improve the research partnership between the NHS, its university partners and the life sciences industries, including the Office for Life Sciences Keynote Speaker 9

Professor Sir Christopher Evans OBE Chairman, Excalibur Group

Founder and Chairman of Excalibur Group, Sir Chris is a highly successful scientist and entrepreneur with numerous prestigious awards and medals for his work. He has built over 50 medical companies from scratch, many from his own ideas and inventions and floated 20 new medical businesses on stock markets in six different countries. Sir Chris has created companies worth over $6 billion employing over 4,000 scientists and built 100s of complex medical laboratories and facilities around the world and positively impacted many millions of lives with his work. He has also raised $2billion for cancer research projects. Founder of Chiroscience, Celsis, Biovex, Merlin, Vectura & and Piramed.

Speaker Profiles

Mohammad Afshar CEO, Ariana Pharmaceuticals

Mohammad Afshar, President and CEO of Ariana Pharmaceuticals, founded the company in 2003. Prior to this, Mohammad was a founder and the Director of Drug Design and IT at RiboTargets, Cambridge, UK. Before that, Mohammad held several positions in academic institutions including at the University of York, UK, and the CRBM of the CNRS in France. He holds a Medical Degree (DCEM), MPhil in Computer Science (DEA), and a PhD in structural biochemistry. Session: Developing Oncology Biomarkers: Lessons from other Therapeutic Areas

Mo Alavijeh CEO, Pharmidex Mo Alavijeh is a bioentrepreneur with >20 years experience in the pharmaceutical industry covering wide range of responsibilities, including R&D, innovation, business development and strategic alliances. His specialist expertise is CNS DMPK, with distinctive competence in neuro-pharmacokinetics. Prior to co-founding Pharmidex, Mo was head of drug metabolism, pharmacokinetic and pharmacodynamic (DMPK/PD) at Vernalis Research, before which he was DMPK team leader at Aventis Pharma. He studied for his PhD at the Institute of Neurology, London.

Session: Imaging in CNS

John Ansell Senior Partner, TranScrip Partners

John Ansell is the kingpin of TranScrip’s business development, covering due diligence, life-cycle planning, product evaluation, business plans and forecasting. He has 20 years of experience in the pharmaceutical industry, followed by over 20 years as a consultant to biotech and pharma companies as well as those providing services to the industry. John is the author of Transforming Big Pharma – Assessing the Strategic Alternatives (Gower Publishing, 2013) as well as of numerous articles on pharma deals. Session: Approaches to Partnering - Part I 10 Speaker Profiles

Davidson Ateh CEO, BioMoti Davidson Ateh is an entrepreneur operating in the life sciences. He has an interdisciplinary scientific background in bioengineering and was a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship. He has won awards for his scientific and commercial activities. Davidson Ateh is the CEO of BioMoti, seeking to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells. Session: Case Study 4 - Ipsen and Syntaxin

Steve Bates CEO, BIA

Steve joined the BIA as its Chief Executive Officer in July 2012. Steve Bates has worked both in biotech and the highest levels of UK government for 15 years. He was Senior Director, External Affairs and Market Access at Genzyme UK and Ireland, during which time he worked on the establishment of the Office for Life Science and was a member of the BIA’s Communications Advisory Committee. Previously Steve was special advisor to John Reid MP in his time as Home Secretary, Secretary of State for Health, Northern Ireland Secretary and Defence Secretary, helping deliver various policy initiatives including the implementation of the Serious Organised Crime Act of 2005. Earlier in his career Steve led the Labour Party media team into the general election of 2001 and was formerly a broadcast business journalist at Dow Jones and ITN. Steve is a Cambridge University graduate.

Session: Life Science Manifesto 2015-20

Morris Berrie Managing Director, Tech Investor

Dr. Morris S. Berrie is the Co-Chairman of TTS Ltd. and Managing Director of Tech Investor Ltd. The former globally facilitates deal flow in the tech transfer / early stage / SME biotech sector whilst the latter advises on ‘the business of science’, i.e. strategic business development and capital raising. Previously he has been CEO at Biotechnology Investment Group, Head of Intelligence at NPG, a Director at Thomson Reuters, and worked at GlaxoWellcome and Schering AG. Session: Case Study 3 - Astex Pharmaceuticals and Otsuka

Dr Eddie Blair Managing Director, Integrated Medicines Dr Eddie Blair is Managing Director of Integrated Medicines Ltd (IML), a company he formed in 2003 to enable personalised medicine by combining diagnostic-type testing with new and existing medicines. He is also a non- executive director (Rem Com Chair) of Immunodiagnostic Holdings PLC, founding director of Integrated Magnetic Systems Ltd (IMSL), and a visiting scholar to the Cambridge University Masters in Bioscience Enterprise programme. He also lectures on personalised medicines and offers occasional bespoke courses based on his best-selling books. Eddie has published more than 40 primary, peer-reviewed papers, including a series on companion diagnostic valuation, and is editor of two personalised medicine journals. Finally, he is named inventor on at least one dozen patents, including tuneable magnetic proteins, the technology being exploited by IMSL.

Session: Developing Oncology Biomarkers: Lessons from other Therapeutic Areas

Martin Buckland CBO, Astex

Martin Buckland has served as Chief Business Officer of Astex since September 2004. He has more than 25 years of commercial and business development experience in the pharmaceutical industry and joined Astex from Elan Pharmaceuticals, where he previously held the position of Vice President of Global Business Development. His prior experience includes a variety of business development and commercial management roles with Quintiles, Xenova and Celltech. Session: Case Study 3 - Astex Pharmaceuticals and Otsuka Speaker Profiles 11

James Caan CEO, Hamilton Bradshaw

James Caan is one of the UK’s most successful and dynamic entrepreneurs. He made his fortune in the recruitment industry, which included the global success of his companies, Alexander Mann Group and Humana International, and he has been building and selling businesses ever since. In 2004 he founded private equity firm Hamilton Bradshaw based in London’s Mayfair. The company specialises in buyouts, venture capital, and real estate and now manages a portfolio of over 30 companies. James is best known for joining the panel of the hit TV show on BBC, Dragons’ Den, where he invested in 14 companies and committed over £1m of investment, over 4 series. In 2012, he was approached by CNBC to host The Business Class, a series which sees him joined by experts from a cross section of industries, looking at the challenges and opportunities faced by UK SMEs. Each 30 minute episode featured an innovative business which was seeking guidance to help it grow in the market place. The popularity of the series saw it re- commissioned for a second series in October 2013. James has written three best-selling books - his autobiography The Real Deal, Get the Job You Really Want and Start Your Business in 7 Days. Get the Job is based on his 30 years in the recruitment industry and reached No. 1 in 3 categories on Amazon, as well as becoming the best-selling practical business book of 2011. In Start Your Business, James uses his experience to help the new generation of entrepreneurs work out if their business ideas are workable and bankable. The book reached No. 2 in the Amazon business chart within two weeks of launching. James is extremely passionate about supporting small businesses and launched a free app, James Caan Business Secrets to help other entrepreneurs on their journey to success. The app was the fastest downloaded business app of 2011 and is regularly ranked in the Top 100 apps ever in Apps Magazine, with over 200,000 downloads to date.

Session: The SCRIP - One Nucleus Debate

Andrew Casey President and CEO, BIOTECanada

In his role as President & CEO of BIOTECanada Andrew is responsible for the day-to-day operations of the Association. In this capacity, he is the primary spokesperson for Canada’s biotech industry communicating on the industry’s behalf with government, regulators, international bodies, media and the Canadian public. He also ensures BIOTECanada plays a central role in partnership with Government in the development of policy relating to Canada’s biotech sector and the member companies of BIOTECanada. Prior to joining BIOTECanada, Andrew served from 2004-2012 as Vice President, Public Affairs and International Trade and Vice President, Government Relations and Communications for the Forestry Products Association of Canada. In those roles he held responsibility for the Association’s government relations, communications, media relations, advertising and international trade undertakings. From 1993-2004 he held the position of Assistant Vice-President, Government Relations with the Canadian Life and Health Insurance Association. Between 1989 and 1993 Andrew held political assistant positions with a Member of Parliament and the Minister of State (Finance). Andrew Casey is a native of Montreal, Quebec. After attending Loyola High School (Montreal) and St. Lawrence CEGEP (Quebec City) he graduated from Carleton University (Ottawa) with a Bachelor of Arts degree in Political Science.

Session: Natural Product Development

Helen Cohen Senior Director, Neurology, Corporate Business Development, Ipsen

Currently VP Endocrinology, Corporate Business Development working for a mid-sized French based pharma company, Ipsen. A highly motivated business development professional with a successful track record of identifying and delivering value-generating opportunities. Previously part of the Neurology team within Ipsen focusing on botulinum toxin development, registration and new toxin opportunities. A broad experience of BD, Alliance Management, Clinical Development, Regulatory Affairs and Project Management within small, medium and large pharmaceutical companies. Trained originally as a pharmacist and now has more than 30 years experience within the pharmaceutical industry.

Session: Case Study 4 - Ipsen and Syntaxin 12 Speaker Profiless

Professor Dr Désiré Collen Chairman and Founder, ThromboGenics

Désiré Collen holds an MD degree and a PhD degree in Chemistry from the University of Leuven (KULeuven), Belgium. He was director of the Center for Molecular and Vascular Biology of KULeuven, and of the Vesalius Research Center of the Flanders Institute for Biotechnology (VIB) in Leuven, Belgium. His research groups initially developed t-PA for treatment of heart and ischemic stroke (with Genentech Inc) and microplasmin for symptomatic vitreomacular adhesion (sVMA) (with ThromboGenics NV). He was founder and chairman of ThromboGenics NV. He was awarded nobility status by King Albert II of Belgium in 2012 and honorary citizenship of Sint-Truiden, Belgium (his birthplace) in 2013.

Session: Case Study 2 - ThromboGenics and Novartis

Kevin Cox CEO, Imanova

Experimental medicine and ‘fast-to-fail’ are important concepts in improving R&D productivity. Molecular and multi-modal imaging can provide early information in-man on disease processes, drug-target engagement and dosing, which help to reduce risks in early-stage drug development. Imanova, a novel JV between the MRC, UCL, ICL and KCL, was established to drive innovation in imaging sciences. We offer a comprehensive range of services, including novel probe development, pre-clinical PET imaging, clinical PET and MRI and full quantitative analysis. With our pharmaceutical company pedigree and world-class science base, we understand drug development and the importance of collaboration, high quality and hitting deadlines Specialities: Neuroscience, Oncology, Inflammation, Respiratory, Infectious diseases, Translational Medicine.

Session: Imaging in CNS

Greer Deal Director, Global Regulatory Services

Greer Deal MCMI MTOPRA, Director of Global Regulatory Services, has an extensive career in the pharmaceutical industry. Her experience includes regulatory affairs, medical information, pharmacovigilance, product development and compassionate use programmes. Greer is passionate about plant-derived products and believes Pharma needs to ‘look back’ in order to go forward and that investors must be bold to help revolutionise this niche area of the life sciences.

Session: Natural Product Development

Dr Barbara Domayne-Hayman Entrepreneur-in-residence, Stevenage Bioscience Catalyst and Chief Business Officer, Autifony Therapeutics

Dr Barbara Domayne-Hayman has a broad range of commercial, fund-raising and general management experience, with many years of business development. She is currently ‘Entrepreneur-in-residence’ at the Stevenage Bioscience Catalyst and Chief Business Officer at Autifony Therapeutics. Previously, Barbara was CEO of Stabilitech, a platform technology company stabilising vaccines and other biologics, for four and a half years. She raised funding, including considerable amounts from non-dilutive sources such as the US Department of Defense as well as the UK’s Technology Strategy Board, established multiple commercial collaborations and built the team from very early stage. Prior to this, she was Commercial Director at Arrow Therapeutics, an antiviral drug discovery and development company, for over four years, until the company was acquired by AstraZeneca in 2007. Before working at Arrow, Barbara was Senior Business Development Manager at Celltech. She previously held senior international commercial positions at Zeneca where she worked for over ten years. She has also consulted in Life Sciences for Ernst & Young Strategy Group, and holds a Sloan Fellowship from London Business School. She has a BA and D.Phil in chemistry, from the University of Oxford. Session: Case Study 2 - ThromboGenics and Novartis Speaker Profiles 13

Dr Neil Fish Director, Business Development, Norgine

Dr Neil Fish is currently Director, Business Development at Norgine and is responsible for in-licensing new opportunities. Prior to this, he was a co-founder of Alizyme plc and was a key part of the team which took the company from start up to a full LSE quoted company. He had a number of key roles including in and out licensing, research manager and was responsible for the companies IP portfolio. Neil was a part of the team that discovered cetilistat (a novel lipase inhibitor to treat obesity), conducted its clinical development and out-licensed the Japanese rights to Takeda. Cetilistat should be launched in Japan in 2014.

Session: Case study 4 - Ipsen and Syntaxin

Susan Foster Member, Mintz Levin

Susan Foster, a Member in Mintz Levin’s London office, works with life sciences companies on data protection matters and agreements relating to research, development and commercialisation. She is qualified in England & Wales as well as California. Susan earned an A.B., with highest honors, from Princeton University (1989), a Ph.D. from Cornell University (1997), and a J.D., with distinction, from Stanford Law School (2000).

Session: Case Study 3 - Astex Pharmaceuticals and Otsuka

Matthew Foy Partner, SR One Matthew joined SR One in 2011 to take the lead in investing SR One’s UK biotech fund. Prior to joining SR One he worked as a consultant for Longbow Capital Partners in London. Before that he was a Vice President of Greenhill & Co, an M&A Investment Bank and Private Equity firm, where he worked for eight years up until 2010 in New York.

Matthew holds a BSc / MA in molecular biology from St Peter’s College, University of Oxford; a Certificate in Corporate Finance from The London Business School and various FSA & SEC qualifications.

Session: SCRIP - One Nucleus Debate

Flic Gabbay Founder and Partner, TranScrip Partners

Flic is one of TranScrip’s specialists in infectious disease, respiratory, renal disease and a pre and peri-registration drug safety expert. She has worked in the industry for more than 30 years and has held a number of senior and CEO positions in both pharma and CRO companies. Flic has worked for pharma and bio-tech companies in Europe and North America on a range of projects including NCEs and biological.

Session: Approaches to Partnering - Part I and II 14 Speaker ProfilessSpeaker Profiles

Steve Gardner Partner, Biolauncher and CEO, RowAnalytics

Steve has built a number of innovative informatics technologies, products and companies in life sciences and healthcare in the US, UK and Europe. He has consulted widely to pharma, biotech, venture firms, the NHS and Government and built consortia in digital health, stratified medicine, biobanking and drug discovery. Steve was previously CTO of BioWisdom, CEO of Synomics and Astra’s Director of Research Informatics. Session: Data Management in Healthcare Research

Staffan Gestrelius Founder and CEO, Capish

Dr. Gestrelius is the founder and CEO of the Knowledge Building company Capish. Capish is specialising in using computers for speeding up the knowledge development within multi-disciplinary projects of pharmaceutical R&D. Focus is on complicated projects and Personalised Medicine. Prior to founding Capish Dr. Gestrelius founded and served as CEO of QlikTech (Nasdaq: QLIK) during the company’s first six years. Dr. Gestrelius was born in Malmö, Sweden, and is a graduate from the University of Lund, Sweden. He is a Master of Science in Technical Physics and Associate Professor in Medical Physiology. He was a pioneer in the simulation of complex biological processes in the 1980-ies. Dr Gestrelius interest in using computers to improve research processes took him to AstraZeneca R&D where he served as IT Director for seven years, before co-inventing the interactive graphical interface QlikView, which is the flagship product of QlikTech. Specialties: Clinical data warehousing Ontology design Patient-centric modelling. Session: Data Management in Healthcare Research Partnering Shaun Grady Vice President - Strategic Partnering & Business Development, AstraZeneca for scientifi c leadership Accountabilities: Vice President Business Development Operations; leading AstraZeneca’s transaction execution, due diligence and Alliance and Integration Management function including early and late stage and on-market licensing and partnering, M&A, and divestments. Career background: ICI, Zeneca, AstraZeneca roles in Corporate, Pharmaceuticals and US Legal departments, HR and Business Development. Major Projects: AZ Merger, Creation of Avecia and Syngenta, Acquisition of CAT, MedImmune and Amylin, Spin out of Albireo. Session: Case Study 1 - AstraZeneca and Bristol Myers Squibb The SCRIP – One Nucleus Debate

Matthias Grossmann Vice President and Principal Consultant, Early Phase Medical Affairs and Consulting, PAREXEL International GmbH

Dr Matthias Grossmann MD, PhD provides a broad range of expert consulting services for Early Drug Development. He has more than 13 years of industry experience in Drug Development. He worked in academia from 1980 to 2000, at the Humboldt University in Berlin, the University of Texas Health Science Centre in San Antonio, the Stanford University School of Medicine and the Technical University of Dresden. He is board certified in Clinical Pharmacology, Clinical Physiology and Pathophysiology.

Session: Monoclonal Antibody Therapeutics

astrazeneca.com/partnering

3618_Partnering_Ad_2013_A4.indd 1 27/09/2013 15:43 Speaker Profiles

Partnering for scientifi c leadership

astrazeneca.com/partnering

3618_Partnering_Ad_2013_A4.indd 1 27/09/2013 15:43 16 Speaker Profiles

John Hodgson Managing Editor, SCRIP Intelligence

John has been a commentator and participant in biotechnology and life sciences research for over three decades as a writer and consultant. His focus has been on the use of deep data of all kinds to dispel market myths and redirect efforts in early commercial decision-making. Session: Case Study 2 - ThromboGenics and Novartis Case Study 4 - Ipsen and Syntaxin The SCRIP – One Nucleus Debate

Ansar Jawaid Director Personalised Healthcare & Biomarkers, AstraZeneca

Ansar has worked in pharmaceutical R&D and commercialisation at AstraZeneca for 11 years. His particular area of expertise is in personalised healthcare across therapeutics, diagnostics and healthcare I.T. He drove the global commercialisation of companion diagnostics for the first lung cancer personalised medicine IRESSA and is currently launching the first ovarian cancer personalised medicine Olaparib in EU and US, with leadership of companion diagnostics globally. Ansar developed AstraZeneca`s personalised healthcare footprint in Asia and Europe and worked on R&D and commercialisation of therapies across therapeutic areas. Ansar has led teams to pioneer genetics and genomics to discover companion biomarkers, rescue drugs, and identify therapeutic targets across oncology, cardiovascular, respiratory and CNS areas. Ansar holds a PhD in Genetics and has published over 20 scientific articles and inventor of four biomarker patented invention.

Session: Developing Oncology Biomarkers: Lessons from other Therapeutic Areas

Harren Jhoti CEO, Astex Pharmaceuticals Harren Jhoti, PhD, has served as president and member of the Board of Directors since July 2011. He co-founded Astex Therapeutics Limited in 1999 and was chief scientific officer until November 2007 when he was appointed chief executive. Dr. Jhoti was awarded the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery by the European Federation for Medicinal Chemistry in 2012 and was also named by the Royal Society of Chemistry as “Chemistry World Entrepreneur of the Year” for 2007. He has published widely including in leading journals such as Nature and Science and has also been featured in TIME magazine after being named by the World Economic Forum a Technology Pioneer in 2005. Dr. Jhoti previously served as a non-executive director of Iconix Inc. and currently serves on the board of the BIA, the UK BioIndustry Association. Before founding Astex Therapeutics in 1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999). Prior to Glaxo, Dr. Jhoti was a post-doctoral scientist at Oxford University. He received a B.Sc. (Hons) in Biochemistry in 1985 and a Ph.D. in Protein Crystallography from the University of London in 1989.

Session: Case Study 3 - Astex Pharmaceuticals and Otsuka

David Kennard Advisor, Corporate Development, Gilead Sciences

Before its acquisition by Gilead Sciences, Dr Kennard was VP, Strategic Alliances YM BioSciences Inc. having joined that Corporation in 2004. Prior to joining YM, he was CEO of NeuroTargets, focused on novel treatments for nerve injury and pain. Dr. Kennard spent eight years prior to that as the COO of SR Pharma, a publicly traded UK-based biotechnology company which developed therapeutic vaccines. He was also with GlaxoSmithKline in development and then strategic planning roles.

Session: Case Study 2 - ThromboGenics and Novartis Speaker Profiles 17

Dr Hanns-Georg Klein, M.D. CEO, IMGM Laboratories GmbH

Following medical school, Dr. Klein started postdoctoral fellowships at the Dept. of Physiology (Munich) and the National Heart, Lung and Blood Institute (Bethesda, MD) working on the genetics of lipid disorders. He then joined the Dept. of Clinical Chemistry (Munich) and founded Medigenomix, now part of Eurofins. Dr. Klein also founded the Center of Human Genetics and Laboratory Diagnostics (Martinsried) and IMGM Laboratories. He is author of numerous publications and serves as a field editor for the Journal of Laboratory Medicine.

Session: Developing Oncology Biomarkers: Lessons from other Therapeutic Areas

Emily Liang Senior Trade and Investment Officer, UKTI China

Emily Liang joined UK Trade and Investment at the British Consulate-General Guangzhou in 2005. For the past 8 years, Emily has focused on the Life Sciences sector (which includes medical devices and biopharm) and has worked with the UKTI team assisting UK companies, such as Alliance Boots, IDC etc, to successfully develop business in southern China. Emily has developed an extensive network of contacts in southern China’s medical sector.

Session: UKTI Showcase

Meredith Lloyd-Evans Founder, BioBridge Ltd

Mr Meredith Lloyd-Evans is founder of BioBridge Ltd and a Partner of the EU’s PharmaSea project which will overcome the bottlenecks in productive marine biodiscovery. BioBridge assists clients in all aspects of the innovation chain from research through start-ups to established companies, including practical project-related assistance and longer-term strategic support and analysis. Current activities include marine and industrial biotechnology and renewables, and long-term support for pharma & biomaterials companies and government agencies.

Session: Natural Product Development

David Mackie Director, Marine Biopolymers

David Mackie is a founding director of Marine Biopolymers, a Scottish based company which is pioneering the re- introduction of commercial scale manufacture of marine origin polymers in the UK, with an especial emphasis on indigenous seaweeds as the key feedstock. Very experienced and has a long background in senior management and marketing positions in both the chemical industry and the forest products industry.

Session: Natural Product Development

John MacLennan Vice Consul, Trade and Investment Officer and USA Sector Lead, UKTI John Maclennan is Vice Consul, Trade and Investment Officer and USA sector lead for the Pharmaceutical and Biotech market sectors. Based in Boston, John works with US companies to help them understand that the UK is a good place to run clinical trials, establish European headquarters and to leverage UK government initiatives in stratified medicine, cell therapy and dementia and other neurological conditions. He also consults with UK companies on their international business strategy, and helps them commercialise their services and products in the US market. John has a Ph.D. from Edinburgh University in structural biology and an MBA with a ‘high tech’ focus from Northeastern University.

Session: UKTI Showcase 18 Speaker Profiles

Robert Miller CEO, Phynova Group

Robert Miller is CEO of Phynova Group Ltd, a life science company located near Oxford that develops plant-derived drugs, medical foods and functional ingredients. He has 30 years experience in the natural products industry in America, Europe and China. He has broad experience in the areas of product development, manufacturing, quality control, and regulatory affairs relating to natural products. In 2006 he established a Joint-Venture research company, Botanic Century Ltd at Zhongguancun Science Park, Beijing.

Session: Natural Product Development

Hitomi Nakai Senior Trade Adviser (Life Sciences), UKTI Japan

Hitomi Nakai is responsible for trade promotion of the UK biotech/pharmaceuticals, medical devices, healthcare and chemicals industries as Senior Trade Adviser of UK Trade and Investment in Japan, ie the world second largest market in terms of sales of pharmaceuticals and medical devices. Hitomi joined the British Consulate-General in 1991, since then supported a large number of British companies’ successful entry to the Japanese market by utilising her local network and marketing expertise.

Session: UKTI Showcase

Matt Newman Sector Manager UK & Australasia, UKTI

Matt Newman is the national Life Sciences Sector Manager for UK Trade & Investment. Utilising the skills from his private sector background Matt has worked extensively on the international agenda with UK life sciences companies for over ten years. Matt has an in depth knowledge of the make up of the UK sector and continues to work collaboratively to develop a number of high profile sectoral strategies which enhance HM Government’s export focused agenda.

Session: UKTI Showcase

John O’Brien Professor of Old Age Psychiatry, Department of Psychiatry, University of Cambridge

John O’Brien is Professor of Old Age Psychiatry in the Department of Psychiatry at the University of Cambridge, having previously been Professor at Newcastle University. His research interests are in dementia and depression in later life, especially the application of imaging biomarkers for diagnosis and monitoring disease progression. He was a member of the NICE Dementia Guidelines Group, is Past President of the International College for Geriatric Psychoneuropharmacology, an NIHR Senior Investigator and the National DeNDRoN Research Lead for Dementia in England. Session: Imaging in CNS

Philip Oliver Managing Director, Sevastopol Advisors Ltd

Philip is a highly experienced pharma senior executive who has brokered over 60 collaboration deals via his past leadership of European partnering for Eli Lilly, and in management consultancy. Philip has extensive knowledge of the European pharma and investment environment and of innovative risk sharing models. He is currently MD of an expert consultancy advising on BD & Licensing, drug development, business planning and grant/investment approaches- and is currently working with several UK and European VCs, biotechs and academic groups.

Session: Plenary Session Speaker Profiles 19

John Parkinson Director, CPRD and Corporate Executive Team, MHRA

Dr. John Parkinson is the Director of the all England, 53 million NHS observational data and interventional research service – the Clinical Practice Research Datalink (CPRD) that combined the services of the GPRD and Research Capability Programme (RCP). John became the first Director of CPRD at its launch in April 2012, and is also a member of the MHRA Corporate Executive Team. John gained his PhD in Biochemistry from the University of Liverpool.

Session: Data Management in Healthcare Research

Dr Richard Pither CEO, Cytox

Dr Richard Pither is CEO of Cytox Ltd. Richard has driven the development of diagnostic and therapeutic products for over twenty years and held senior R&D and leadership positions in global Pharmaceutical companies including GE Healthcare (Medical Diagnostics), UCB-Celltech, Lorantis and Amersham plc.. Richard has a BSc in Cellular and Molecular Pathology from Bristol University. His PhD, also at Bristol, was gained in the field of immunology and vaccine design, followed by post-doctoral research at Harvard. Session: Developing Oncology Biomarkers: Lessons from other Therapeutic Areas

Jennifer Pierce Partner, Charles Russell

Jennifer Pierce is a partner at Charles Russell and heads its commercial intellectual property group. She advises on IP protection and strategy together with all forms of IP and commercial agreements relating to life sciences. She is included in IAM’s global list of patent and technology licensing specialists. Jennifer began life sciences work at BTG, where she advised on licensing and was a member of the team that floated the company. Since returning to private practice, she has worked with a variety of life sciences organisations, ranging from major pharmaceutical licensing companies to spin-outs to Governmental organisations.

Session: Case Study 2 - ThromboGenics and Novartis

Thomas Plath, PhD Director, Business Development, ICON

Thomas is Director Business Development at ICON clinical research, a full service CRO and leading medical imaging service vendor. Thomas works for more than 10 years in medical imaging and clinical research in different imaging CROs. He is a trained biochemist with many years of pre-clinical research in academia and Biotech. He managed more than 30 medical imaging studies and gained significant experience in CNS clinical studies: e.g. Alzheimer´s disease, stroke, glioblastoma, brain hemorrhage.

Session: Imaging in CNS

Keith Powell Chairman, Domainex

Keith has been in Biotechnology since it started. Having worked for GSK and ICI/Zeneca in genetics/molecular biology he led several large groups including Discovery, finally running the patent group. He then left for the USA and worked in a company on the West Coast, Maxygen, leading the small molecule group through the IPO and growing a business which eventually spun out as “Codexis”. On coming back to the UK, Keith worked with a fund called BBSF and acted as CEO for several of the companies in the portfolio, including Spear, sold to Advent International. He led Domainex through a merger with NCE to form a successful business in protein structure-based chemistry. Polytherics was built through organic growth since 2005 to a company of >30 people. Keith is currently chairman of Domainex, Biomoti and Canbex and has a portfolio of other interests.

Session: Case Study 1 - AstraZeneca and Bristol Myers Squibb 20 Speaker Profiles

Ken Powell Executive Chairman, QChip

Executive Chairman of Q-Chip a Cardiff based company developing novel delayed release formulations. His past roles include: Founder and CEO of Arrow Therapeutics Ltd (an antiviral drug discovery company acquired by Astra-Zeneca PLC for $150 million in February 2007). Professor of Cell Biology and Virology UCL. Head of Biology for the Wellcome Foundation Limited. Fulbright Fellow and Faculty member Baylor College of Medicine, Houston Texas. Over the last 15 years Ken has been involved in developing UK biotechnology companies utilising different business models. His companies have been involved in significant licensing deals with Pfizer, Novartis, Astra-Zeneca and GSK.

Session: Case Study 1 - AstraZeneca and Bristol Myers Squibb

Jonathan Savidge Director of Business Development, Bicycle Therapeutics Dr Savidge is currently Director, Business Development at Bicycle Therapeutics and was responsible for negotiating the company’s recent partnership agreement with Thrombogenics N.V., announced in September 2013. He has also recently acted as business development consultant to several biotech companies (including Syntaxin and ReNeuron). Prior to this he spent 5 years at Evotec having responsibility for partnering internal pipeline programmes in CNS and pain, executing two significant deals with Roche.

Session: Approaches to Partnering - Part I

Able Ureta-Vidal COO and Founder, Eagle Genomics

With over 14 years bioinformatics experience and a scientific background in molecular biology and immunovirology (PhD from the Pasteur Institute, France), Abel first got to grips with bioinformatics tools and code in the early 90s whilst working on viral phylogenetic studies. After his PhD, he joined the effort at Genoscope (Evry, France) in ramping up the human genome project, putting in place the automatic gene annotation system for human chromosome 14. In 2001, Abel moved to the European Bioinformatics Institute (Cambridge, UK) where he led the Ensembl comparative genomics team until 2007. He founded Eagle shortly before graduating from the Cambridge Judge Business School MBA program in 2008. For the last 5 years he has been a driving force within the executive team at Eagle, supporting the strategy and partnership activities as well as setting up a world-class company operation able to adapt to market demand. This has enabled the company to sustain its growth and extend its activities horizontally from the traditional pharma/biotech sector into sectors as diverse as plant breeding, animal health, consumer goods and food safety. Session: Data Management in Healthcare Research

Priya Varadarajan India Lead Life Sciences, UKTI India Priya Varadarajan is the national lead for Life Sciences for UKTI in India. She is based in Bangalore, the biotech capital of the country. Priya is a Chartered Accountant by profession and gives UK SMEs the added advantage of the business side as well when she is advising them on markets and opportunities. Priya has helped over 100 UK SMEs over the last 6 plus years understand the potential of working with a huge market, helping access this complicated market and also easing out a lot regulatory hurdles through her fantastic networks and contacts.

Session: UKTI Showcase Speaker Profiles 21

Tristan Vaughan PhD Senior Director, Research, Antibody Discovery and Protein Engineering (ADPE), MedImmune

Tristan first joined Cambridge Antibody Technology (CAT) in 1993. Following the acquisition of CAT by AstraZeneca, he is currently responsible for generating around two thirds of the antibody portfolio for MedImmune, AstraZeneca’s biologics business. His teams utilises the core technologies of phage and ribosome display, as well as in vivo platforms to discover and engineer mAbs and, together with Protein Sciences and High Throughput Screening teams, support four disease areas. Prior to his current appointment, Tristan held key operational responsibilities as part of the successful CAT-AstraZeneca strategic alliance and prior to that for CAT’s Milestone and Royalty based Alliances, including that with Human Genome Sciences that delivered Benylsta®. He also developed the platform technology to build antibody libraries of > 1010 members and was also a key member of the team that discovered Humira®. Before joining CAT, he was a postdoctoral fellow at the University of Toronto. Tristan is a University of Leeds graduate from the Genetics Department.

Session: Monoclonal Antibody Therapeutics

Evelyne Vuaridel Senior Evaluator Drug Delivery, Debiopharm

Evelyne Vuaridel joined Debiopharm in 1994 where she works in the Business Development & Licensing department as New Opportunities Officer. In her current role she is responsible for the search and identification of novel therapeutic molecules in Europe, and the evaluation process up to due diligence. Prior to joining the scouting team, Evelyne Vuaridel spent 14 years in the company as a drug delivery expert. She held management positions in the development of controlled release formulations, advanced oral delivery formulations and nanotechnologies. During 3 years she was a research associate at the State University of New York and three years as the head of topical formulations at Zyma/Novartis. She holds a pharmaceutical diploma and a PhD from the ETHZ .

Session: Approaches to Partnering - Part I and II

Martin Welschof CEO, Opsona Therapeutics

Martin Welschof is the CEO of Opsona Therapeutics Ltd. a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including inflammatory related disease indications, such as transplant rejection and cancer. The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin.

Session: Monoclonal Antibody Therapeutics

Guy Wood-Gush CEO, Deontics

Guy has been CEO of Deontics Ltd for the last two years. Previously he was a practising surgeon, a clinical research physician at Eli Lilly, a Healthcare investment banker, CEO of Cancer Research Ventures (CRUK), and Chairman of Cambridge Cognition Ltd. Deontics Ltd. has world-leading clinical decision support technology originating from research carried out at CRUK, Oxford University and UCL.

Session: Data Management in Healthcare Research

David Wyper Director, SINAPSE

Professor David Wyper is the Director of SINAPSE - www.sinapase.ac.uk - an academic pooling group, specializing in medical imaging, established by the Scottish Funding Council in 2007. Prior to this he was Director of the Department of Clinical Physics and Bioengineering and Associate Director of Research and Development in NHS Greater Glasgow and Clyde. He helped to establish Scottish Health Innovations Limited and was the SHIL Board’s NHS representative from 2002 -2010. 22 Programme

08.00 Registration

08.15-09.00 St James Suite Life Science Manifesto 2015-20 Chair Steve Bates BIA

Harriet Fear 09.15-09.25 Opening of Genesis 2013 One Nucleus

09.25-10.45 Plenary Session

Plenary Session Chair Philip Oliver Sevastopol Advisors

Enabling Clinical Research to Stimulate Growth Dr Louise Wood 09.25-09.45 Department of Health

A Strategic Corporate Venture Fund Perspective on their Roel Bulthuis 09.45-10.05 Head of Merck Serono Ventures, Merck Serono SA Role in the Modern Biopharma Sector Wolfson Institute for Biomedical Research, UCL

Sir Salvador Moncada 10.05-10.25 An Academia-Industry Interface that Enables the Professor of Experimental Biology and Discovery of Innovative Medicines Therapeutics, UCL

Mike Ward The Industry in 2014: Predictions, Hopes and Fears 10.25-10.45 SCRIP Intelligence

10.45-11.15 Coffee Break

11.15-12.15 Parallel Streams - Innovative Strategies to Bridging the R&D Funding Gap St James Suite Westminster Suite Whittle Room Albert Suite Case Study 1 Case Study 2 Developing Oncology Natural Product AstraZeneca and Bristol ThromboGenics and Biomarkers: Lessons from Development Myers Squibb Novartis other Therapeutic Areas Chair Chair Chair Chair Mike Ward John Hodgson Eddie Blair Greer Deal SCRIP Intelligence SCRIP Intelligence Integrated Medicines GRS

Speaker Speaker Speakers Speakers Shaun Grady Desire Collen Hanns-Georg Klein Meredith Lloyd-Evans AstraZeneca ThromboGenics IMGM Labortories GmbH BioBridge Limited Richard Pither Andrew Casey Cytox BIOTECanada Panellists Panellists Panellists Panellists Jennifer Pierce Ansar Jawaid David Mackie Keith Powell Charles Russell AstraZeneca Marine Biopolymers Domainex Barbara Domayne-Hayman Mohammad Afshar Robert Miller Stevenage Bioscience Catalyst Arianan Pharmaceuticals Phynova Ken Powell and Autifony Therapeutics Q Chip David Kennard Gilead

12.15-13.30 Sir Christopher Evans Lunchtime Keynote Address Excalibur Group Programme 23

13.30-14.30 Parallel Streams - Innovative Strategies to Bridging the R&D Funding Gap

St James Suite Westminster Suite Whittle Room Albert Suite Case Study 3 Case Study 4 Approaches to UKTI Showcase Session UK Trade & Investment and Office for Life Astex and Otsuka Ipsen and Syntaxin Partnering Science Investment will present the UK strengths Chair Chair Introduction Mike Ward John Hodgson Flic Gabbay Chair SCRIP Intelligence SCRIP Intelligence TranScrip Partners Matt Newman Speaker Speaker Speakers Speakers Harren Jhoti Helen Cohen John Ansell USA Astex Pharmaceuticals Ipsen TranScrip Partners John Maclennan Martin Buckland Charles Brigden Astex Pharmaceuticals China Amgen Emily Liang Panellists Panellists Evelyne Vuaridel India Susan Foster Davidson Ateh Debiopharm Priya Varadarajan Mintz Levin BioMoti Japan Morris Berrie Jonathan Savidge Neil Fish Bicycle Therapeutics Hitomi Nakai Tech Transfer Summit and Norgine Tech Investor Neill Mackenzie Georg Buchner Roji Life

14.30-15.00 Coffee Break

15.00-16.00 Parallel Streams - Innovative Strategies to Bridging the R&D Funding Gap

St James Suite Westminster Suite Whittle Room Albert Suite Data Management in Imaging in CNS Approaches to Antibody Based Healthcare Research Partnering Therapeutics

Chair Chair Chair Chair Abel Ureta-Vidal Mo Alavijeh Flic Gabbay John Burt Eagle Genomics Pharmidex TranScrip Partners Polytherics Speaker Speaker Speaker Speakers John Parkinson Kevin Cox Michael Jackson Martin Welschof CPRD Imanova Eisai Opsona Therapeutics Abel Ureta-Vidal John O’Brien Matthias Grossmann Panellists Eagle Genomics University of Cambridge PAREXEL International GmbH Charles Brigden Panellists Panellists Amgen Panellists Staffan Gestrelius Thomas Plath Evelyne Vuaridel Tristan Vaughan Capish Knowledge ICON DebioPharm MedImmune Steve Gardner David Wyper Matthew Foy BioLauncher SINAPSE SR One Guy Wood-Gush Adolfo Cotter John Ansell Deontics NeuroImage TranScrip Partners

16.00-16.30 Coffee Break

16.30-17.30 The SCRIP - One Nucleus Debate: The Industry in 2018: Predictions, Hopes and Fears

Whittle Room Chair John Hodgson SCRIP Intelligence Speakers Shaun Grady Mike Ward AstraZeneca SCRIP Intelligence Matthew Foy James Caan SR One Hamilton Bradshaw

17.30 -17.40 Rebecca Parkes Cancer Research UK Catalyst Club Cancer Research UK

17.40 -19.30 Drinks Reception 24 Partnering 21 23 20 22 Fleming Room 19

Whittle Room Bio Cafe Catering 43 1 46 16 44 13 47 17 45 3 10 14 48 6 18 2 7 11 15 5 1 8 12 4 9

Catering

Lifts Help Desk Lifts

49a 81 80 Lifts Press Room Press 49 79 51 50 78 77 76 Benjamin Britten 58 Refreshments Room 55 60 59 71 65 Talent Lounge 74

56 61 63 64 66 75 83 Catering 57 62 Catering 66

68 69 70 82 Catering pExhibitor List 25

44 A4P Bioanalytical Group 4 MedGenesis

56 Alpharmaxim 5 MRC Technology Catering

46 Andrew Porter 82 Naturejobs Catering 45 APL 21 NIHR Biomedical Research Centre,Oxford 66 Arkivum Limited 13 Norwich Research Park

82 18 63 AstraZeneca

9 Novasecta 15

Refreshments

21 17 47 Boyd Consultants Talent Lounge 70

14 18 Ontario Ministry of Economic Development

24 12 83

20 16

9 17 Canadian High Commission

74

13 69 23 11 83 Pharma Training International 76

19 75

8 75 Charles Kendall BioLogistics 22 10

68 81 Pharmaterials 7 77 70 Cogent SSC

Lifts 62 Pharmidex Pharmaceutical Services Lifts 76 Cryostore 68 Pharma Publications 77 Dora Wirth (Languages) 66 66 65 Bio Cafe 78 19 Phastar 79 16 Dundee Cell Products 6 71 64 57 Public Health England 3 5 Catering 43 Eagle Genomics 48 QuickSTAT

1 2 46 4 7 Edinburgh BioQuarter 80

43 58 59 atering Fleming Room Fleming 47 1 6 Scottish Development C Partnering 44 20 Enterprise Europe Network International

48 81

45 Desk 63 67 ERA Consulting 58/59 SCRIP Intelligence Help Help a 49 49 60 62 61 55 First Sight Media 65 Simbec Research

50 49 Flanders Investment & Trade 74 Society of Biology 49a Flanders House 15 Stockholm-Uppsala 51 50 Forresters 1 TranScrip Partners Lifts 55 56 57 2 Gregory Fryer Associates 3 UbiFrance 12 Greiner Bio-One 10/11 UKBIF 24 Harlow District Council 22/23 UKTI 80 Illingworth Research 51 UMI3 Room Whittle Room Whittle 64 KISS Communications 60 Welsh Government

14 LES 79 World Courier Benjamin Britten Catering 69 Locate in Kent 78 London & Partners 71 London Life Science 8 Mathys & Squire FLANDERS, BELGIUM HIGHEST DENSITY OF BIOTECH COMPANIES WORLDWIDE * (*) according to new Scientist magazine 2012

Join us for the session with the eminent Professor Désiré Collen about the deal between Flemish company ThromboGenics and Novartis and find out how the biotech focussed business environment in Flanders has provided the fundamentals. Venue: parallel stream in the St. James Suite on floor 4 at 11.15am.

Find out what Flanders can do for you and your company and visit us at our stand!

www.investinflanders.com

Flanders Investment & Trade | 1a Cavendish Square GB-London W1G OLD | United Kingdom T +44 20 73 07 77 10 | [email protected] www.investinflanders.com | twitter.com/InvestFlanders

Adv_GenesisConferentieUK2013_200x287.indd 1 21/10/2013 17:15:54 The Genesis Talent Lounge 27

The Talent Lounge

One Nucleus is delighted to introduce a new addition to Genesis 2013, the Talent Lounge which is a dedicated area for careers, training and recruitment for company executives, academic researchers and advisers to interact. The Talent Lounge is where providers and advisers in the area of skills, recruitment and training can be accessed by delegates.

It is an often used phrase that ‘people are our biggest asset’, but do you develop your company’s human capital effectively?

• What skills gaps you feel are hard to fill?

• What training courses are available to life science research and business executives?

• Are you using the optimal recruitment strategy to find the right people?

• What career opportunities does the life sciences sector offer?

• Does your science writing get the message across?

The Genesis 2013 Talent Lounge will have experts from Nature, Cogent, Pharma Training International, HRS, UCL, Queen Mary University, Sciad, Birkbeck University, George James, the University of Cambridge and the Society of Biology available to answer and discuss any of the above questions in a non-sales environment. VISIT THE FRENCH PAVILION FLEMMING ROOM - STAND 3

For the 2013 edition of Genesis, Ubifrance has once again brought together a delegation of French companies working in the life sciences sector. Hosted on the Ubifrance stand in the Flemming Room, the French companies will be promoting a range of products and services in the biotechnology and pharmaceutical sector. These companies are looking to reinforce their professional contacts and explore new partnering opportunities between France and the UK.

UBIFRANCE, the French agency for international business development lies at the heart of France’s public sector export support framework.

The London office of the French Trade Commission Ubifrance promotes trade and business development between France and the UK. It offers a range of services to French companies including B2B events, conferences, networking opportunities and individual partnering services.

Come to stand 3 in the Flemming Room to meet with the French delegation, or pick up one of our catalogues at the event. Should you wish for more information, please use the contact details below. We look forward to meeting you at Genesis 2013 and wish you a successful event. Contact: Katie Docwra, Trade Development Adviser, Healthcare and Biotechnology Sector [email protected]

For our programme of events visit our website: http://www.ubifrance.com/uk VISIT THE FRENCH PAVILION FLEMMING ROOM - STAND 3

For the 2013 edition of Genesis, Ubifrance has once again brought together a delegation of French companies working in the life sciences sector. Hosted on the Ubifrance stand in the Flemming Room, the French companies will be promoting a range of products and services in the biotechnology and pharmaceutical sector. These companies are looking to reinforce their professional contacts and explore new partnering opportunities between France and the UK.

UBIFRANCE, the French agency for international business development lies at the heart of France’s public sector export support framework.

The London office of the French Trade Commission Ubifrance promotes trade and business development between France and the UK. It offers a range of services to French companies including B2B events, conferences, networking opportunities and individual partnering services.

Come to stand 3 in the Flemming Room to meet with the French delegation, or pick up one of our catalogues at the event. Should you wish for more information, please use the contact details below. We look forward to meeting you at Genesis 2013 and wish you a successful event. Contact: Katie Docwra, Trade Development Adviser, Healthcare and Biotechnology Sector [email protected]

For our programme of events visit our website: http://www.ubifrance.com/uk

Exhibitor Profiles 31

A4PBio provide CRO oversight, project Alpharmaxim Andrew Porter Limited is a laboratory management and consultancy services relocations specialist and the only company in order to deliver regulatory compliant “Words are…the most powerful drug…” in the sector in Europe to adopt GxP bioanalysis and bio-logistics solutions to the Kipling. standards. The need to relocate equipment life science sector. is integrated with the movement of A4PBio offer client-focused solutions in Whether to enhance investor appeal, temperature controlled materials, data and global laboratory selection, through assay demonstrate the place for your product, dangerous goods as part of an overall lab development and validation, study sample add value to customers or increase relocation package. The firm understands analysis, data reporting and document attraction to investigators, the need for clear the post move IQ/OQ/PQ requirements, review. Combining this with bespoke communication has never been greater with every move focused toward the most logistics solutions for the pro-actively particularly in speciality areas. efficient and effective uptime sequencing managed transport of time and temperature Alpharmaxim are experts at helping you requirement. critical biological samples and cell-based maximise the science behind your brands. With its fleet of more than 60 vehicles, therapies. We focus on speciality healthcare clients, the firm provides professional support A4PBio’s flexible and scalable resources, where the need to change beliefs is to organisations operating across the using considerable Pharmaceutical, paramount, and clearly communicate value European life sciences landscape, as well as Biotechnology and CRO experience, deliver through science to all stakeholders. We further afield using its extensive network of individually built, cost effective, scientifically take time to understand your needs and to worldwide partners. robust and regulatory compliant outsourcing provide tailored recommendations that will or consultancy solutions. truly meet them. Our communications truly are your most powerful drug! John Best, European Sales Director [email protected] www.A4Pbio.com Will Hind www.andrewporterltd.co.uk Stand 44 [email protected] Stand 46 www.alpharmaxim.com Stand 56

APL is a leading Contract Development Arkivum provide a large scale, long term, AstraZeneca is a global, innovation- and Manufacturing Organisation within cost effective data archiving service with a driven biopharmaceutical business that Scandinavia. We have been established for unique 100% data integrity guarantee. focuses on the discovery, development and over 30 years with four production sites in With large volumes of data - which are commercialisation of prescription medicines, Sweden that offer services that cover the growing year on year - which need to be primarily for the treatment of cardiovascular, entire development process. We specialise in retained, organisations face ever increasing metabolic, respiratory, inflammation, both sterile and non sterile manufacturing storage costs as they retain this archive data autoimmune, oncology, infection and of biopharmaceuticals and pharmaceuticals on expensive media such as disk. neuroscience diseases. AstraZeneca operates along with drug product formulation Arkivum’s full managed service provides an in over 100 countries and its innovative development and analytical method elegant, low cost, highly secure and easy to medicines are used by millions of patients development. APL is highly flexible, we are use solution to these challenges. worldwide. For more information please visit: also very dedicated to our customers and we The reductions in capital expenditure, www.astrazeneca.com. can help you with a small project right up to improvements in operational efficiency and manufacturing your product. Our facilities the certainty of compliance means that our are fully cGMP compliant and are regularly clients see significant benefits in a very short Gerhard Symons inspected by EMA, FDA, customers corporate time-scale. [email protected] QA. www.astrazeneca.com Cathy Brode, Business Development Stand 63 Manager and Head of Compliance Mattias Nyström, Business Development [email protected] Manager www.arkivum.com [email protected] or (sales@apl. Stand 66 se) www.apl.se/en Stand 45 Eagle on-demand Bioinformatics expertise when you need it

• Short-notice access No more capacity worries to expertise Experiencing fluctuations in demand in your bioinformatics team? • Bunch the work • Want to test a new idea or technology? together or spread • it out • Seen something interesting in the literature and lacking the time or resources to try it out? • Use Eagle staff only Project deadline approaching, but don’t have enough staff to deliver? when needed • • Utilise our expertise Pre-purchased, guaranteed availability for anything from Recruiting and retaining a bioinformatics team with sufficient experience and exploring new appropriate skills can be a headache – so why not outsource? research ideas to We are bioinformatics experts who work on any task under the sun that relates maintenance tasks to genomic data or placing data into the context of the genome. • Eagle’s consultants A dedicated Eagle bioinformatician is assigned to the project to act as a single point all have many of contact and has instant access to our entire team’s knowledge and experience. years’ experience in Eagle’s on-demand service is available on your site or remotely. It is ideal for bioinformatics getting assistance with projects that are too small or loosely defined to be able to specify in full for traditional outsourcing.

Example usage: 6 0 hours over 6 months

MAR 5 55 6 1 2 3 4 5 7 8 9 10 11 12 18 13 14 15 16 17 6 49 24 19 20 21 22 23 30 25 26 27 28 29 31 2 USAGE BALANCE 47 APR 20 27 6 1 2 3 4 5 7 8 9 10 11 12 18 13 14 15 16 17 10 17 24 19 20 21 22 23 25 26 27 28 29 USAGE BALANCE

MAY 3 14 6 1 2 3 4 5 7 8 9 10 11 12 18 13 14 15 16 17 24 19 20 21 22 23 30 25 26 27 28 29 31 7 USAGE 7 BALANCE JUN 7 0 6 1 2 3 4 5 7 8 9 10 11 12 18 13 14 15 16 17 24 19 20 21 22 23 30 25 26 27 28 29 USAGE BALANCE

JUL 4 -4 Top up time! 6 1 2 3 4 5 7 8 9 10 11 12 18 13 14 15 16 17 24 19 20 21 22 23 30 25 26 27 28 29 31 USAGE BALANCE

[email protected] www.eaglegenomics.com +44 (0)1223 654481

0283_2012_Elastic A4.indd 1 12/10/2012 10:39 Exhibitor Profiles 33 Eagle on-demand Bioinformatics expertise when you need it

Boyd Consultants was established in Canadian High Commission At Charles Kendall BioLogistics, we 2005 and provides a range of expertise The Canadian Trade Commissioner choose not to be all things to all men, which and skills central to the development of Service is a network of more than 1000 is what makes us unique in our field as an pharmaceutical & biotechnology medicinal trade professionals working in Canadian Events Logistics company in the Pharma and products and medical devices. embassies, high commissions, and Life Sciences market sector. We offer our We are based in the UK with offices located consulates located in 150 cities around the clients a complete and dedicated door-to- in Cheshire and Cambridgeshire. world and with offices across Canada. The door exhibition service. Working closely Our consultancy services offer a cost- Trade Commissioner Services in London with our overseas offices and agents, we effective solution for those requiring expert helps companies that are looking to trade, will continue to support British exhibitors at assistance in order to expedite development, invest or develop innovation and R&D Pharma & Life Science events throughout add value to their product, and reach those partnerships. We provide advice, vital the world. Working in close co-operation milestones. contacts, market information and other with our parent company, Charles Kendall Professional Services services in order to facilitate trade between Freight, we are able to offer all our exhibition • Product Development Canada and UK. clients a tailor made solution to any event, • Regulatory Affairs anywhere in the world. • Regulatory Medical Writing Amir Golbang, PhD, Trade • Short-notice access No more capacity worries • Statistics and Data Management Commissioner, Healthcare & Life Michael Barrett to expertise • Medical Monitoring Support Sciences [email protected] Experiencing fluctuations in demand in your bioinformatics team? • Business Support [email protected] http://www.charleskendallfreight.com/ • Bunch the work • • Training www.tradecommissioner.gc.ca/eng/home. freight/exhibitions Want to test a new idea or technology? jsp Stand 75 • Prof Alan Boyd, Managing Director together or spread Stand 17 it out • Seen something interesting in the literature and lacking the time or [email protected] resources to try it out? www.boydconsultants.com • Use Eagle staff only Stand 47 Project deadline approaching, but don’t have enough staff to deliver? when needed • • Utilise our expertise Pre-purchased, guaranteed availability for anything from Recruiting and retaining a bioinformatics team with sufficient experience and exploring new appropriate skills can be a headache – so why not outsource? research ideas to We are bioinformatics experts who work on any task under the sun that relates The Cogent Group comprises Cogent Cryo-Store is a dedicated facility for the DWL is a specialist translation service maintenance tasks to genomic data or placing data into the context of the genome. SSC, The Cogent Technical Apprenticeship Service and The National Skills Academy storage of biological material, disaster provider for the pharmaceutical industry A dedicated Eagle bioinformatician is assigned to the project to act as a single point for the Process Industries. Cogent Group recovery material and research libraries providing translation solutions, in a wide • Eagle’s consultants in a totally secure temperature controlled range of languages for both traditional and of contact and has instant access to our entire team’s knowledge and experience. Companies work in an alliance with all have many employers to develop, design and deploy conditions. It provides an invaluable resource emerging markets and clinical trial sites, in years’ experience in Eagle’s on-demand service is available on your site or remotely. It is ideal for skills and education solutions for the science for the biotechnology, pharmaceutical and the fields of: getting assistance with projects that are too small or loosely defined to be able to industries. medical industries. REGULATORY AFFAIRS, bioinformatics Our storage temperatures range from CLINICAL RESEARCH, specify in full for traditional outsourcing. The approach is evidence-based and employer-led, with the ambition to ambient to liquid nitrogen. PHARMACOVIGILANCE, The facility is GxP compliant and is MEDICAL RESEARCH, Example usage: hours over months boost sector innovation, growth, and 6 0 6 competitiveness through skills. Cogent continuously monitored and alarmed, MANUFACTURING, ensuring sample temperatures are MEDICAL DEVICES, MAR 5 55 Group skills solutions are adopted by every 6 1 2 3 4 5 consistently maintained. Full emergency MEDICAL PUBLISHING AND 7 8 9 10 11 12 size of organisation, from SMEs through to 18 13 14 15 16 17 6 49 24 19 20 21 22 23 back-up systems are constantly on stand by, MARKETING COMMUNICATIONS. 30 25 26 27 28 29 global companies. Cogent works right across 31 2 USAGE BALANCE 47 covering storage units, power supply and With over 50 years of experience, DWL has APR 20 27 the science sector including life sciences and 6 1 2 3 4 5 data. developed a solid, trustworthy and cost- 7 8 9 10 11 12 industrial science. 18 13 14 15 16 17 10 17 24 19 20 21 22 23 Cryo-Store is licenced by The Human Tissue effective service. 25 26 27 28 29 USAGE BALANCE Authority (HTA) and for the storage of GMM. MAY 3 14 www.cogent-ssc.com Samuel J. Wirth, Managing Director 6 1 2 3 4 5 7 8 9 10 11 12 18 13 14 15 16 17 Stand 70 Malcolm Wilkinson Kim Shouler, Business Development 24 19 20 21 22 23 30 25 26 27 28 29 31 7 USAGE 7 BALANCE [email protected] Director JUN 7 0 www.cryostore.co.uk [email protected] 6 1 2 3 4 5 7 8 9 10 11 12 18 13 14 15 16 17 Stand 76 dwlanguages.com 24 19 20 21 22 23 30 25 26 27 28 29 USAGE BALANCE Stand 77

JUL 4 -4 Top up time! 6 1 2 3 4 5 7 8 9 10 11 12 18 13 14 15 16 17 24 19 20 21 22 23 30 25 26 27 28 29 31 USAGE BALANCE [email protected] www.eaglegenomics.com +44 (0)1223 654481

0283_2012_Elastic A4.indd 1 12/10/2012 10:39 ABOUT FLANDERS

In Flanders when we’re hungry we make waterzooi. We make fashion for Paris and endives for New York. We make cinema, theatre and the best loved chocolate in the world. We make bicycles and champion cyclists. We make the finest beers and the best medicines for headaches. We make history and the future.

We make patients feel better and people feel at home.

We make that everybody understands us. We make steel cord and lace. We make video screens larger and energy greener. We make the tallest towers and islands in the sea.

When we want to cheer ourselves up we make funny costumes and have a parade. We make literature and architecture. We make scientists creative and craftsmen innovative. We make music and the stages to perform it on. In Flanders we make anything. We just don’t make a lot of fuss.

FLANDERS – IMAGINATION WORKS

Flanders is the autonomous northern region of Belgium with Brussels as its capital. It is the gateway to Europe. Exhibitor Profiles 35

Eagle is an expert provider of bioinformatics Edinburgh BioQuarter is a unique Dundee Cell Products Ltd (DCP) is consultancy across a wide range of concept, bringing together scientists from a dynamic and innovative bioreagents commercial sectors, covering human the University of Edinburgh and NHS Lothian and life science services company that health, plant sciences, food, animal health, with commercial research companies to commercialises high quality research tools and consumer products. Through its collaborate and accelerate the development for biochemistry, molecular biology and cell multidisciplinary team headquartered in of new drugs, diagnostic tools and medical biology research and provides services in Cambridge, UK, Eagle can provide innovative devices to treat diseases. This enterprise these areas to the life sciences community, and proven end to end solutions to support has made Edinburgh a leading European including researchers in the pharmaceutical all of your bioinformatics research needs. destination for translational medical industry, biotechnology companies as well The Eagle team are experts in a range of research. 6 years ago the University joined as in academic research institutions. Key bioinformatics tools for both the commercial forces with Scottish Enterprise and NHS proteomics-based technologies dedicated and academic sectors, and are able to Lothian to create the Edinburgh BioQuarter. to assist the development of safer drugs provide an impartial opinion on the most Its aims were to foster deeper links with quicker include ToxProfile, BioMarkId, effective approach for your problems. As industry through collaborative research; to PhosProfile and TargetId and are delivered well as the application of bioinformatics create new companies based on Edinburgh’s through Dundee Cell Proteomics a division tools and technologies, Eagle is active in research base, and to encourage a culture of of the company. developing and improving them through commercialisation in the NHS and among a number of commercial and academic academic researchers. An experienced Commercialisation Team was established Dr Paul Ajuh (CEO) or Dr Chloe Steels, collaborations, such as Ensembl, Taverna and in 2010 to deliver these aims and in just Account Manager & Technical Specialist TraitTag. Eagle’s client base covers the globe, over three years has spun out seven new customerservices@dundeecellproducts. including Europe, US and the Far East. life sciences businesses and negotiated a com number of major industrial collaborations, [email protected] Richard Holland, CBO as well as generating 100 new product www.dundeecellproducts.com [email protected] or business concepts from its Innovation Stand 16 www.eaglegenomics.com Competition. Stand 43 Shona Cameron, Head of Marketing and Communications [email protected] www.bioquarter.com Stand 7

ERA Consulting has served the biopharmaceutical industry for over 25 years providing regulatory, strategic and technical guidance for the development of First Sight Media are a video production medicinal agents (>450 to date), including company that will help you to reach your recombinant protein/antibody therapeutics, customers and target an audience with a Enterprise Europe Network is your vaccines, ATMPs (cell/tissue/gene therapies), message that engages and informs. gateway to competitiveness and innovation. natural products and small molecules. Our For over 20 years we have delivered creative The Network supports businesses to consultants are drawn from biotech, pharma, live event, training and promotional video make the most of the opportunities biomanufacturing, regulatory, translational productions and as a result have built up an in the European market. We help local medicine and academic scientific experienced and dedicated team of media organisations to find the right business backgrounds to provide experienced professionals who pride themselves in partners, build their innovation capacity and support from product inception through exceeding client requirements. meet their capital requirements. development to commercialisation. Services Online is our forte and we excel at live Enterprise Europe Network is strong of offered also include regulatory training and on-demand video streaming. This is approximately 600 business support and specialist due diligence. With offices enhanced for conferences and webinars organisations in 54 EU and non-EU countries, in London, Washington D.C, Germany and through our bespoke presentation promoting international cooperation locally. Australia, ERA maintains a global presence software iPresenter, allowing us to deliver Our services are specifically designed for and interacts closely with European, US and high definition video of your speaker Small and Medium-sized Enterprises (SMEs) other regulatory authorities. simultaneously with their presentation slides but are also available to all businesses, across the internet. research centres and universities across Adam Levy, Business Development Please visit our website which contains Europe. [email protected] many examples of our work together with www.eraconsulting.com testimonials supporting the services we Chris Farmakis, EC Funding Manager Stand: 67 provide. [email protected] Steve Webber, Business Development www.een-london.co.uk Manager Stand 20 [email protected] www.firstsightmedia.co.uk Stand 55 36 Exhibitor Profiles

Flanders Investment and Trade is a government development agency at the Belgian Embassy in London. We provide Flanders House At Forresters, we provide clear, sensible confidential expert advice on doing business Flanders is a dynamic and prosperous region and practical advice on intellectual property, on the European continent. Our services are within Belgium, in the heart of Europe. As including patents, trade marks, designs and tailored to your business needs and are free a devolved nation, Flanders has a lot of copyright, in the UK and across the world. of charge. We can help you find the right autonomy and responsibilities, like in the We like to take a collaborative approach with location and get you in touch with the right field of health care, economic development, our clients, drawing on their knowledge to specialist or partner. Flanders Investment research and innovation policies. Flanders ensure that we understand what they want and Trade will guide you through our tax belongs to the top when it comes to health to achieve. incentives and available grants to maximise care and new technologies. Flanders’ Care, We look to deliver our guidance in plain, opportunity. Feel free to contact us on our overarching strategy for the health jargon-free language and are not afraid to [email protected] or +44 (0)207 307 care sector, aims to constantly upgrade recommend a particular course of action, if 77 10 regarding any query on doing business our care system through innovation and we think it is right for you. in Europe. entrepreneurship. No wonder that Flanders We have a well-established and sizeable is a leading life sciences region with several life-sciences department, with extensive life sciences hubs. Today, biotech companies, experience in getting and litigating patents Geert De Proost, Representative of the research centres and bio incubators in the UK and Europe. Government of Flanders flourish in state of the art science parks [email protected] clustered around our largest universities. www.flanders.be/london Like previous years and with the support of Charlotte Teall Stand 49a the Representation of the Government of [email protected] Flanders in the United Kingdom (Flanders www.forresters.co.uk House), several Flemish universities and Stand 50 research centres are present at Genesis to showcase their work and look for collaborations with British partners. Geert De Proost [email protected] www.flanders.be/london Stand 49

Harlow Council is leading the development of the Harlow Enterprise Zone which will be providing space focussed on the needs of the Life Science sector. GFA is an expert consultancy and services Greiner Bio-One is a high quality Uniquely located between London and provider to the pharma and biotech manufacturer and supplier to the Life Cambridge and with excellent access to industry, providing innovative, world class Science, Pharmaceutical, Diagnostic and Stansted Airport, talk to us about locating at Regulatory, Clinical Research, Quality and Clinical markets. We offer a vast portfolio the Harlow Enterprise Zone and the benefits Pharmacovigilance solutions to get your of products for research and clinical for your business which include: products to market. Our team of 30 experts applications. Business Rates discounts with experience gained in a variety of Simplified Planning industry backgrounds will provide you with The Bioscience product range provides Access to innovation support through the bespoke, comprehensive development highly innovative and novel solutions within Anglia Ruskin University’s Med Tech Campus. programme services; as part of a full plan laboratory plastics, combining 50 years of An exceptional and well connected location or stand-alone services, to meet your manufacturing knowledge with the latest at the heart of the London Stansted commercial objectives. This year, we are technology and research. Cambridge Corridor. celebrating our tenth anniversary and The Preanalytics division focus on primary anticipate further growth and continued Andrew Bramidge, Project Director – specimen collection for clinical applications success in providing early phase clinical Enterprise Zone and is one of the worlds leading providers of services and regulatory services across the [email protected] evacuated blood collection systems. product development process from pre- www.harlow.gov.uk clinical to post marketing. Stand 24

Angela Bonich, Director, Business James Siddorns, Business Development Development Manager [email protected] [email protected] www.gf-associates.co.uk www.gbo.com Stand 2 Stand 12 Exhibitor Profiles 37

KISS is a creative communications Illingworth Research is a unique, agency built on the principle of keepings leading European Contract Research things simple. Simple is better. In an ever LES Britain & Ireland (LES B&I) is one Organisation (CRO) offering a full range of increasingly complicated world it’s needed of 32 member societies of the global clinical development services and medical more than ever. As a multi-disciplinary umbrella organisation LES International photography services to the pharmaceutical, agency with deep experience in the life (LESI) and is also one of the most active. It healthcare, biotechnology and medical science sector our services include strategy is the society for professionals and business device industries. and messaging workshops, branding, people interested in licensing, the transfer ResearchNurses.co our sister organisation design, advertising, digital, exhibitions, of technology, and the commercialisation specialise in the provision of highly bespoke communications, training and, of intellectual property rights. The Society experienced research nurses for both in conjunction with our partner Zyme provides unique opportunities for on-site and homecare projects for the Communications, specialist life science PR multidisciplinary education and networking, pharmaceutical, healthcare, biotechnology and marketing. locally and globally. Through regular meetings of council, committees and special and medical device industries. We have over www.kisscom.co.uk a decade of experience providing research interest groups, members of the society www.zymecommunications.co.uk are kept abreast of national and European nursing support to clients, and are now the Stand 64 UK’s leading independent research nurse Commission legislative proposals. They provider. can also become involved at international level, and they have the opportunity to contribute to debate on crucial topical Kieran Casey, Director of Business issues. Conferences, regular meetings and Development special events in London and throughout [email protected] the regions offer members excellent www.illingworthresearch.com opportunities to explore licensing-related Stand 80 subjects and to meet fellow practitioners. www.les-bi.org Stand 14

Locate in Kent. Kent has a vibrant life science cluster of more than 130 companies London & Partners is the official Mathys & Squire has over 100 years of employing more than 6,000 employees, promotional organisation for London. Our experience in providing Intellectual Property with more than 50 of these in the MedTech company attracts and delivers value to services to UK industry. Our attorneys work sector. Companies such as Abbott, Aesica, business, students and visitors. We work in across a number of technical disciplines, DiaSorin, Novartis and Smiths Medical partnership with organisations across the including biotechnology, pharmacology, benefit from the county’s location close to world to achieve our goal – that London healthcare & medical devices, and chemistry. London, available skills, dedicated sites and is recognised as the best big city on Earth. We have a global track record in securing facilities and finance and support. The Kent London & Partners connects international valuable Intellectual Property rights for cluster offers many opportunities including businesses to London, helping them set universities, government, start-ups and investment, partnership working and up, succeed and grow. Our expert and spin-out companies. Our attorneys also company growth. Discovery Park Enterprise experienced professionals can advise you on specialize in freedom-to-operate and due Zone offers 1.5m sq ft of dedicated state of every aspect of locating and doing business diligence activities, and we are particularly the art laboratories and specialist space, and in London. proud of our extremely high success rate is already home to 40 companies including in both defending and challenging patents more than 20 life sciences companies such www.londonandpartners.com before the European Patent Office. Most as Pfizer and Mylan, employing nearly 1,000 Stand 78 importantly, we develop IP strategies that skilled staff. align with our clients’ commercial plans. Paul Wookey, Chief Executive Locate in Kent, [email protected] Dr William Johnson, Associate www. locateinkent.com [email protected] Anna Stone, Leasing Manager www.mathys-squire.com Discovery Park, anna.stone@discov- Stand 8 ery-park.co.uk www.discovery-park.co.uk, Stand 69 38 Exhibitor Profiles

MedGenesis Limited was formed London Life Science MRC Technology (www.mrctechnology. to design, implement and market London has an active, highly concentrated org) is an independent life science software solutions for the international and globally competitive life science sector technology transfer charity, offering pharmaceutical, medical device and incorporating numerous medical facilities, professional services to organisations within cosmetic industries. world leading academic institutions the academic, charity, biotechnology and Our lead product is the TARA (Tools and a diverse range of companies. The pharmaceutical sectors globally. Services for Adverse Reaction Assessment) city provides the perfect laboratory for include IP management and research system. Designed from the outset by research and development, producing and development for diagnostics, small pharmacovigilance professionals supported unique opportunities for collaboration and molecules and therapeutic antibodies. MRC by experienced programmers, TARA offers a investment. Technology bridges the gap between basic layout that is consistently simple, intuitive, LondonLifeScience.com is a portal to help medical research and commercialisation, user friendly and most importantly cost organisations navigate this complex research helping early discoveries progress to clinical effective, making it suitable for all sizes of landscape. It creates an online interface application. companies and academic units. TARA is between organisations in the capital, currently deployed in several countries , and bringing the best life science minds together Duncan Young, Business Development several follow up products are in late stage and encouraging collaboration, whilst Manager development. competitively driving the sector forward. [email protected] LondonLifeScience.com has been developed www.mrctechnology.org by London Medicine (a division of London Stephen Bentley, Director Stand 5 Higher, the body representing higher Mick Marks, Director education institutions within London). [email protected] To learn more, follow us on Twitter @ www.tarapv.com LondonLifeSci. Stand 4 Amy Lightstone, Project Manager, Lon- don Medicine [email protected] www.LondonLifeScience.com Stand 71

Naturejobs is the global career resource The NIHR Biomedical Research Centre, and jobs board for scientists. We can help Oxford is a partnership between the you throughout your job search and your research expertise of the Oxford University Norwich Research Park is a major centre career: Hospitals NHS Trust and Oxford University’s for bio and medical technology research, • View science careers advice Medical Sciences Division supporting comprising a community of academic and • Research employers translational ‘bench to bedside’ research. commercial scientists. It encompasses • Set up job alerts Oxford is host to one of the largest world-class science research at bioscience • Upload your CV Biomedical Research hubs in Europe institutes, the University of East Anglia • Sign up to our newsletter recognized internationally for delivering (Medical and Pharmacy Schools, Biomedical • Search for jobs on your mobile outstanding teaching and research with Research Centre, Clinical Trials Unit) and the • Interact via our blog global impact. Supported by significant Norfolk and Norwich University Hospital. The Naturejobs provides a wide range of career investment into state-of-the-art facilities Park offers access to state-of-the-art facilities advice, science recruitment news and and research activities our scientists are and expertise. We have 3,800 sq m of mixed science jobs, all free to access at naturejobs. consistently at the forefront of innovative laboratory and office accommodation for com. research, from basic science through drug start-ups and established companies. Our Employers using the site range from trials to clinical practice. We understand new hub building Centrum has a further top pharmaceutical and biotechnology the value of collaboration and welcome 2,300 sq m and will open spring 2014. companies to highly-respected academic the opportunity to build partnerships with and government institutions and charities. industry, academia, medical organisations Dr Matthew Hills, Business-Science Take advantage of Naturejobs and grow your and charities. Liaison science career with us. Alex Prior, Business Development matthew.hills@norwichresearchpark. [email protected] Manager com www.naturejobs.com [email protected] www.norwichresearchpark.com Stand: 82 www.oxfordbrc.nihr.ac.uk and www. Stand 13 medsci.ox.ac.uk Stand 21 Exhibitor Profiles 39

Pharmaterials is a contract service Novasecta is a resource-based strategy Ontario, Canada company providing pharmaceutical consultancy for life sciences companies. The International Trade Branch of the Ministry of Economic Development, development for oral, inhaled, topical and parenteral routes of drug delivery with We have worked with a diverse set of clients Trade and Employment is introducing cGMP manufacturing for early phase clinical to create lasting value for their businesses in the following Ontario companies to the trials. Development work is underpinned three areas: Genesis Conference: BioScape Medical by our comprehensive expertise in Research & Development Imaging, BioPharma Services, KalGene pharmaceutical materials science, salt Crafting R&D strategies, transforming R&D, Pharmaceuticals, NeuroImage and Sernova selection, polymorphism, amorphous achieving more from technology platforms Corporation. These firms provide a wide materials and formulation. We have a wealth and assets, actively managing R&D portfolios. range of services, technologies and products of experience in the oral delivery of low Commercial to the healthcare sector and share a solubility drug substances and have taken Building go-to-market strategies, achieving reputation for quality and innovation. many formulations to the clinic. more from commercial franchises, growing business units. Our core services: Corporate •Salt selection, polymorph screening and Creating partnership strategies, deciding Laurie D’Souza, International Market co-crystal formation. on M&A possibilities, enabling business Consultant •Formulation development (Oral, IV, topical & development deals, securing financing. [email protected] www.SourceFromOntario.com inhalation). •cGMP manufacture of clinical trial material. Our specialist consultants all have prior Stand 18 •Solid state testing & Raman mapping of professional experience from pharma, APIs, excipients and final drug products. biotech, medical devices, CROs, scientific •Amorphous quantification. institutions, or life sciences consulting.

Grace Ong, Engagement Manager Euvian Tan, Senior Associate Christopher Landeg www.novasecta.com Director of Business Development Stand 9 [email protected] www.pharmaterials.co.uk Stand 81

PTI As part of Informa plc, the multinational publishing and conference company, Pharma Publications is a dynamic media Pharmidex provides high quality Pharmaceutical Training International (PTI) organisation, specialising in dedicated experimental preclinical ADMET/PK data, is a bespoke training company providing publications for the Life Sciences Industry. critical to drug discovery programme interactive, up-to-date and topical courses, With a product portfolio of publications progression. We have comprehensive addressing the latest concerns facing the like, IPI - International Pharmaceutical in house laboratory facilities as well as pharmaceutical and biopharmaceutical Industry, JCS - Journal for Clinical Studies bioanalytical laboratories at the Stevenage industry. With the experience of our Advisory and JPC - Journal for Patient Compliance, we BioScience Catalyst. Extensive in-vitro & Board we continuously revise our content look into the best practice in outsourcing in-vivo assay options enable the provision to ensure that your course is relevant and management for the Pharmaceutical & of tailored studies to meet individual project timely. PTI also understands your work Bio-Pharmaceutical Industry. Providing needs. Through extensive knowledge commitments, which is why we supply peer-reviewed articles and analysis on of drug discovery and development, distance and on-site training courses for drug discovery, drug development, clinical Pharmidex has been able to deliver a high when time can be a precious commodity. research, manufacturing, packaging, supply level of customer satisfaction and forge Our programmes are delivered worldwide chain management, patient adherence several strategic international alliances, and have the flexibility to train small teams and health outcomes, we provide focussing on operations in the following to larger organisations across multiple comprehensive guidelines to help the areas: in vitro ADMET, in life, Pharmacology, countries. industry grow. We endeavour to be your CNS Drug Discovery, Bioanalysis, Metabolite Victoria Biscoe, Customised Training one-stop-shop for all your marketing to the Identification and Bioimaging. Consultant industry. [email protected] Dr. Martin Barrett, Business Orsolya Balogh, Central Administrator Gerald Okullo Development Manager [email protected] Training Account Manager [email protected] www.ipimediaworld.com, www.jforcs. [email protected] www.pharmidex.co.uk com, www.jforpc.com www.pti-global.co.uk Stand 62 Stand 61 Stand 83 40 Exhibitor Profiles

PHASTAR is a specialist CRO offering QuickSTAT Public Health England is an executive statistical consultancy and clinical trial For over 30 years, QuickSTAT has played agency of the Department of Health. We reporting, by providing expert statisticians a critical role in managing clinical trial operate a nationwide, integrated public and programmers or managing and logistics for all phases of research and health service through a network of over delivering in-house projects. Our number drug development. We specialise in global 5000 staff, working with and alongside one priority is to ensure that the work we shipping of time and temperature-sensitive others to protect and improve the produce is of the highest quality: every clinical research samples, investigational public’s health and wellbeing and reduce project PHASTAR undertakes is supervised drugs, clinical trial supplies, and dangerous inequalities. on methodology and utilises internal goods. Public Health England combines the processes designed to ensure optimal Our long-standing clients include the microbiology, diagnostics, research and quality. Services include production of TFLs, leading pharmaceutical, biotech and clinical manufacturing capabilities of the former study design, modelling and simulation, trial supply companies, CROs and central Health Protection Agency with expertise advice on handling missing data across labs around the world. in cancer and other aspects of health phase I to IV trials. We can manage and Our specialists are available 24/7, delivering improvement and intelligence. deliver whole clinical trial programs, or give complex logistical solutions and expert We aim to be the authoritative national you advice on a trial you are planning. knowledge for your clinical trials. voice and expert service provider for public QuickSTAT has invested in leading edge, Mohamed Hasham, Business health ensuring everyone is protected from client-centric technology, uniquely designed Development Executive threats, providing products and services and to support clinical trial logistics. [email protected] working in partnership with the industry to www.phastar.co.uk deliver innovative healthcare solutions. Gurmeet Sidhu, Business Development Stand 19 [email protected] Sarah Elliott, Business Development Business Development Department [email protected] [email protected] [email protected] www.gov.uk/phe http://quick.aero/quickstat Stand 57 Stand 48

Scottish Development International SCRIP Intelligence - vital pharmaceutical Simbec Research provides contract is the economic development agency for industry ideas and global signals for your clinical trial services to the international Scotland and is a joint venture between the career, your business and your future. pharmaceutical and biotechnology sectors, Scottish Government, Scottish Enterprise SCRIP Intelligence subscribers receive developing new medicinal products and Highlands & Islands Enterprise. a glimpse of the future from the daily including devices and diagnostics. We have Since it was founded 11 years ago, SDI has drumbeat of crucial events across the been servicing international pharmaceutical, transformed Scotland’s economic outlook, sector spectrum – from biotech start-ups to biotechnology and related drug companies attracting some of the world’s biggest multinational giants; research boutiques to for over 35 years and specialise in First-in- companies to locate in the country, growing generic manufacturers; and suppliers large Human studies of new molecular entities Scottish exports and creating over 19,000 and small. and biologicals. Trials conducted range from new jobs. Experienced writers and analysts are based Phase I studies in healthy subjects through Scotland hosts one of the largest life in key geographic markets to convey all to Phase II trials in patients. All services science clusters in Europe with significant aspects of the industry. Global hot topics are on one site, including full bioanalytical international presence in research, such as orphan diseases, personalised backup, Central Laboratory and related development and manufacturing. With a medicine, and management strategies from support services. Simbec is one of a select long and remarkable history of medical and developed to emerging markets are covered group of companies that has received scientific discovery stretching back 200 years, with local depth and insight. Supplementary Accreditation from the Scotland has always been at the forefront of MHRA. medical innovation. Paul Morkel, Marketing Manager [email protected] Basia Kondratowicz, Senior Business Fiona Jefferson, International Senior www.scripintelligence.com/freetrial Development Executive Executive Stand 58 - 59 [email protected] [email protected] www.simbec.com www.sdi.co.uk Stand 65 Stand 6 Exhibitor Profiles 41

Stockholm-Uppsala is the region where business and research thrive! Our region The Society of Biology is a single unified is a hot-bed of creative cross-disciplinary TranScrip Partners is a rapidly growing voice for biology; advising Government and collaboration and, together, we are building cutting-edge contract organisation that influencing policy; advancing education international businesses and delivering real supports biopharmaceutical product and professional development; supporting research breakthroughs that will help solve development and life cycle management. our members and engaging and advancing the world’s health problems. We’re open- TranScrip Partners are strategic thinkers public interest in the life sciences. The minded and productive. Our state-of-the-art who do, and doers who think strategically. Society represents a diverse membership infrastructure and talented scientists provide Working for more than 80 companies across of individuals, learned societies, and other all the services and support you’ll need. 4 continents, TranScrip has shown it can organisations. www.suls.se. play a crucial role in facilitating the selection and progression of drug candidates into Stand 74 Ola Björkman clinical studies and on to POC, including [email protected] demonstration of potential value, and, Ywonne Bölja where necessary, securing funding and [email protected] regulatory approvals. TranScrip’s expertise Stand 15 further extends across the design and implementation of clinical development plans, risk management, regulatory and product differentiation strategies. www.transcrip-partners.com Stand 1

UBIFRANCE, The French Agency for International Development, promotes UK Bio-Incubators offer flexible laboratory UK Trade & Investment the Government trade between France and the rest of the and office space, scientific and business department that helps UK based companies world, offering its clients a diverse range of support services to early stage and growing succeed in an increasingly global economy. customised services. Each office within the life sciences companies. Our range of expert services are tailored international network has specialised Trade The UK Bio-Incubator Forum (UKBIF) is a to the needs of individual businesses to Advisers working in various sectors to assist collection of Bio-Incubators located across maximise their international success. We French companies with their commercial the UK. The forum exists to promote the provide companies with knowledge, advice development strategies abroad. UBIFRANCE Bio-Incubators, share best practice and co- and practical support. UK Trade & Investment UK will be present at the 2013 edition of ordinate support for the life sciences early also helps overseas companies bring high GENESIS on stand 3 with a delegation of stage business community. quality investment to the UK’s dynamic French biotechnology companies looking economy – acknowledged as Europe’s to meet potential partners in the United Miranda Knaggs, Chair best place from which to succeed in global Kingdom. Miranda.knaggs@stevenagecatalyst. business. We provide support and advice For more details on the French delegation, com to investors at all stages of their business please contact Katie Docwra. www.ukbioincubation.com decision-making. UK Trade & Investment Stand 10 & 11 offers expertise and contacts through Katie Docwra a network of international specialists [email protected]. throughout the UK, and in British Embassies Stand 3 and other diplomatic posts around the world.

Matt Newman, Senior Sector Manager [email protected] www.ukti.gov.uk Stand 22 & 23 42 Exhibitor Profiles

World Courier The Welsh Government’s Life Sciences Incorporated in 1969 World Courier is the sector team is focussed on business largest and most experienced specialty growth and commercial success. We are courier with a network of over 152 coordinating a strategy for the life sciences company-owned offices, all ISO certified sector in Wales that enhances and develops and GxP compliant. World Courier has set our existing clusters of expertise and the benchmark for Bio-Pharmaceutical, time-sensitive transportation and is UMIP® is The University of Manchester’s facilitates the creation of an ecosystem the acknowledged leader in delivering agent for intellectual property which is vibrant and dynamic. The team has customised temperature-controlled commercialisation. UMIP’s three operational access to a range of funding mechanisms solutions to the international bio- teams: Scouting; IP Development and and related programmes and infrastructure pharmaceutical industry. With in-house Partnering; and Enterprise and Business to support inward investment to Wales. scientists to understand your needs World Development are responsible for identifying, We also have joined up routes across Courier can recommend, supply and protecting and commercialising the government departments to support replenish packaging and refrigerants to University’s IP. UMIC® is the University’s academia and the NHS to pursue and share ensure the integrity of your temperature- Innovation Centre-its bioscience incubators research excellence to benefit the economy controlled shipments. Documentation and include the successful Manchester and the people of Wales. regulatory requirements are managed to Bioscience Incubator and the Core ensure your shipment complies with local Technology Facility (CTF). UMIC® also Mel Crisp, Head of New Business requirements. We are dangerous-goods, provides conferencing and meeting room Development, Life Science Sector Dry-Ice, liquid-Nitrogen and controlled- facilities. UMIP® and UMIC® are divisions of [email protected] substance specialists. The University of Manchester Innovation www.wales.com/business Stand 60 Group Ltd; www.umi3.com. David Spillett, Business Development [email protected] Manager , Biopharm Services www.umip.com [email protected] [email protected] www.worldcourier.com www.umic.co.uk Stand 79 Stand 51

Patent and Trade Mark Attorneys

We make it our business to understand yours

Clear, straightforward advice for all your intellectual property issues

London : +44 (0) 20 7283 8989 Birmingham : +44 (0) 121 236 0484 Merseyside : +44 (0) 151 647 6746 Munich : + 49 (0) 89 2441 299 0

email : [email protected] website : www.forresters.co.uk ON Hub 43

ON Hub

This newly launched One Nucleus initiative creates an opportunity for life science executives to access meeting space and office facilities at various life science hubs across the UK and further afield. Here they can, for example, use WiFi and business services, have coffee and refreshments whilst meeting business colleagues by pre-arrangement or share a common interest when travelling.

Key Facts

Facilities are available to holders of an ON Hub membership card. The card is free to life science executives upon registration with One Nucleus.

Each card will be for the exclusive use of the holder and will carry a unique identification Hub locations will be listed on the One Nucleus website along with contact details ON Hub members can contact an individual hub in advance to arrange access. Specific terms and conditions may apply that diffier from hub to hub Access to a hub will require one additional form of photo ID to gain access to facilities

Participating Hubs

One Nucleus, Granta Park, Cambridge Hilton Doubletree Allegiance Programme

www.onenucleus.com www.hiltonsme.hiltonbusinessonline.com

London & Partners, London Bridge, London Allegiance is a new programme from our support supplier, Hilton Doubletree, crafted specifically for www.londonandpartners.com SME businesses and offering savings when visiting any of the Hilton Worldwide portfolio. London & Partners, the official promotional organisation for London, attracts and delivers value Joining Allegiance is free and benefits are as follows: to business, students and visitors. The team works in partnership with organisations across the world to 10% saving on accommodation and 5% o meetings achieve the goal – that London is recognised as the and events, food, drinks, WiFi, car parking and more best big city on Earth. More than 100 hotels across the UK BioPark, Welwyn Garden City Save money on business and leisure bookings Patent and Trade Mark Attorneys www.biopark.co.uk Network with other Allegiance members at exclusive Located close to the heart of London’s biomedical events We make it our business to understand yours technology community, BioPark provides specialist Easy booking with our dedicated Allegiance portal facilities and support for bioscience and health technology businesses, encouraging growth and the and 24/7 reservations line Clear, straightforward advice for all your development of new products and technologies. Simple to claim – simply present your Allegiance intellectual property issues Life Sciences Hub Wales card at check out

An iconic building in Cardiff Bay will create the focal Free to join and easy to save – just quote your point for life sciences in Wales. The Hub is the place to Allegiance card number when you book meet people who know about life sciences in Wales A dedicated meetings and events facilitator to help London : +44 (0) 20 7283 8989 and internationally. you and your perfect venue Birmingham : +44 (0) 121 236 0484 Merseyside : +44 (0) 151 647 6746 The Hub will have great facilities for meetings, Plus – Allegiance members can now enjoy 5% off at Munich : + 49 (0) 89 2441 299 0 networking and events. The Hub will be the go-to Living Well Health Clubs too! place for life sciences businesses to start, develop and email : [email protected] grow. To be launched on 5 March at BioWales. website : www.forresters.co.uk For more information about ON Hub, please contact [email protected]. Your Brilliant Ideas Our Insight

UK Trade & Investment is the government Come speak to our expert department that helps UK-based companies advisors at stand 22 & 23 succeed in the global economy. in the Fleming Room.

We also help overseas companies bring their high- To find out more contact quality investment to the UK’s dynamic economy, [email protected] acknowledged as Europe’s best place from which www.ukti.gov.uk to succeed in global business.

UK Trade & Investment offers expertise and contacts through its extensive network of specialists in the UK, and in British Embassies and other Date: diplomatic offices around the world. We provide companies with the tools they require to be competitive on the world stage.

Genisis_brochure_v6.indd 2-3 22/10/2013 15:39 Your Brilliant Ideas Our Insight

UK Trade & Investment is the government Come speak to our expert department that helps UK-based companies advisors at stand 22 & 23 succeed in the global economy. in the Fleming Room.

We also help overseas companies bring their high- To find out more contact quality investment to the UK’s dynamic economy, [email protected] acknowledged as Europe’s best place from which www.ukti.gov.uk to succeed in global business.

UK Trade & Investment offers expertise and contacts through its extensive network of specialists in the UK, and in British Embassies and other Date: diplomatic offices around the world. We provide companies with the tools they require to be competitive on the world stage.

Genisis_brochure_v6.indd 2-3 22/10/2013 15:39

Join us at one of the largest UK Life Sciences conferences 6th & 7th March 2014 Conference, Exhibition and Partnering Wales Millennium Centre, Cardiff, Wales

International speaker programme Focus on delivering industry growth 1:1 Partnering meetings

Visit the website for more information and to register www.biowales.com

WG20363 Welsh Government Genesis Ad.indd 1 21/11/2013 10:36 London’s premier Life Science & Healthcare networking conference genesis 2014

9 December 2014

Queen Elizabeth II Conference Centre Westminster, London, UK

onenucleus.com/genesis

ON1038_Genesis_Ad_A4.indd 1 18/11/2011 14:20